US · OMER · BIOTECHNOLOGY
Omeros Corporation (OMER) intrinsic value and stock valuation
$13.21as of 2026-11-21 · Mkt cap 958.97M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Omeros Corporation DCF and intrinsic value
InvestorsCraft values OMER with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from OMER’s statements →
Omeros Corporation Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Lexicon Pharmaceuticals, Inc. (LXRX) $1.53
- 4D Molecular Therapeutics, Inc. (FDMT) $10.23
- Ocugen, Inc. (OCGN) $0.77
- Neumora Therapeutics, Inc. Common Stock (NMRA) $0.33
- Bicycle Therapeutics plc (BCYC) $2.90
- Fulcrum Therapeutics, Inc. (FULC) $3.69
- ADC Therapeutics S.A. (ADCT) $1.28
- Gossamer Bio, Inc. (GOSS) $10.72
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-122.8M | -$-169.26M | -$-164.53M | -$-163.39M | -$-173.62M |
| Net income | -$-3.35M | -$-156.81M | -$-117.81M | $47.4M | -$-111.41M |
| EPSd | -$-52.75K | -$-2.7M | -$-1.88M | $755.8K | -$-1.79M |
| Operating cash flow | -$-116.09M | -$-148.8M | $74.7M | -$-86.48M | -$-109.72M |
| Capital expenditure | -$-70K | -$-170K | -$-430K | -$-110K | -$-280K |
| Free cash flow | -$-116.16M | -$-148.97M | $74.3M | -$-86.6M | -$-110M |
| Total assets | $325.6M | $277.1M | $378.3M | $591M | $419.3M |
| Total debt | $239.1M | $207M | $361.6M | $342M | $347.8M |
| Net debt | $229.5M | $203.6M | $354.5M | $331M | $247M |
| Total equity | -$-121.23M | -$-182.61M | -$-24.98M | $85.7M | $23.8M |
| Cash and short-term investments | $171.8M | $90.1M | $171.9M | $194.9M | $157.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 | $1.39M |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | -$-1.39M |
| Research and development expenses | $81.3M | $119.5M | $114.9M | $112.7M | $118.8M |
| Selling, general and administrative expenses | $41.5M | $49.7M | $49.7M | $50.7M | $53.5M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $122.8M | $169.3M | $164.5M | $163.4M | $172.2M |
| Cost and expenses | $122.8M | $169.3M | $164.5M | $163.4M | $173.6M |
| Interest income | $5.06M | $11.3M | $16.3M | $4.06M | $20K |
| Interest expense | $0.00 | $24.7M | $30.8M | $22.7M | $19.7M |
| Depreciation and amortization | $960K | $950K | $920K | $950K | $1.39M |
| Ebitda | -$-1.83M | -$-157M | -$-143.16M | -$-158.38M | -$-170.49M |
| Operating income | -$-122.8M | -$-169.26M | -$-164.53M | -$-163.39M | -$-173.62M |
| Total other income/expenses, net | $120M | -$-13.37M | -$-10.39M | -$-18.64M | -$-17.93M |
| Income before tax | -$-2.8M | -$-182.63M | -$-174.92M | -$-182.03M | -$-191.55M |
| Income tax expense | $2.01M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-3.35M | -$-156.81M | -$-117.81M | $47.4M | -$-111.41M |
| Weighted average shares outstanding | $63.5M | $58.2M | $62.7M | $62.7M | $62.3M |
| Weighted average diluted shares outstanding | $63.5M | $58.2M | $62.7M | $62.7M | $62.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $171.8M | $90.1M | $171.9M | $194.9M | $157.3M |
| Net receivables | $36.3M | $36.8M | $6.72M | $242M | $82.5M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $215.7M | $134.1M | $217.9M | $443.2M | $248M |
| Property, plant and equipment, net | $12.5M | $17.6M | $20.6M | $23.3M | $30M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $110M | $143M | $160.4M | $147.7M | $171.3M |
| Total assets | $325.6M | $277.1M | $378.3M | $591M | $419.3M |
| Accounts payable | $4.76M | $5.91M | $7.71M | $5.99M | $13.4M |
| Short-term debt | $23.4M | $27M | $13.7M | $98.7M | $5.25M |
| Deferred revenue | $2.47M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $78.1M | $79.5M | $53.3M | $136.4M | $51.8M |
| Long-term debt | $215.8M | $180.1M | $347.9M | $243.3M | $342.6M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $368.8M | $380.2M | $349.9M | $368.9M | $343.7M |
| Capital lease obligations | $13.5M | $19.4M | $23.3M | $26.7M | $34.4M |
| Total liabilities | $446.9M | $459.7M | $403.3M | $505.3M | $395.5M |
| Common stock | $720K | $580K | $610K | $630K | $630K |
| Retained earnings | -$-913.7M | -$-910.35M | -$-753.53M | -$-635.72M | -$-683.13M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | -$0.00 | $0.00 | $0.00 |
| Total equity | -$-121.23M | -$-182.61M | -$-24.98M | $85.7M | $23.8M |
| Total investments | $162.1M | $86.7M | $164.7M | $183.9M | $56.5M |
| Total debt | $239.1M | $207M | $361.6M | $342M | $347.8M |
| Net debt | $229.5M | $203.6M | $354.5M | $331M | $247M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-3.35M | -$-156.81M | -$-117.81M | -$-182.03M | -$-191.55M |
| Depreciation and amortization | $960K | $950K | $920K | $950K | $1.39M |
| Stock-based compensation | $8.19M | $10.5M | $11.7M | $0.00 | $0.00 |
| Change in working capital | $33.7M | $29.7M | $247.4M | -$-118.97M | -$-14.11M |
| Accounts receivable | $30.5M | $40M | $245.7M | -$-175.07M | -$-34.31M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $0.00 | $0.00 | $0.00 | -$-10.66M | $14.6M |
| Net cash provided by operating activities | -$-116.09M | -$-148.8M | $74.7M | -$-86.48M | -$-109.72M |
| Investments in property, plant and equipment | -$-70K | -$-170K | -$-430K | -$-110K | -$-280K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $126M |
| Net cash used for investing activities | $164.5M | $82.2M | $27.5M | -$-127.56M | $193.7M |
| Common stock issued | $47M | $0.00 | $0.00 | $410K | $8.38M |
| Common stock repurchased | $0.00 | -$-11.85M | -$-4.65M | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-42.17M | $62.9M | -$-106.08M | $124.3M | $6.32M |
| Net change in cash | $6.26M | -$-3.71M | -$-3.9M | -$-89.8M | $90.3M |
| Cash at end of period | $9.66M | $3.4M | $7.11M | $11M | $100.8M |
| Operating cash flow | -$-116.09M | -$-148.8M | $74.7M | -$-86.48M | -$-109.72M |
| Capital expenditure | -$-70K | -$-170K | -$-430K | -$-110K | -$-280K |
| Free cash flow | -$-116.16M | -$-148.97M | $74.3M | -$-86.6M | -$-110M |
Line items
Line items
Line items
About Omeros Corporation
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
- CEO
- Gregory A. Demopulos
- Employees
- 175
- Beta
- 2.55
Explore
Frequently asked questions
What is the intrinsic value of Omeros Corporation (OMER)?
InvestorsCraft does not currently publish an intrinsic value for OMER. How the IC value is calculated.
Is OMER undervalued?
InvestorsCraft does not publish an undervaluation signal for OMER at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.